Creatinine Measurement Market Size is expected to register a substantial growth rate between 2022 and 2028, on account of the rising prevalence of renal disorders in developing as well as developed economies. Creatinine measurement tests are used to examine the performance of kidneys in filtering waste from blood. Creatinine measurement via urine or blood samples can help healthcare professionals to determine the performance of the kidneys as well as devise specific treatment plans.
Initiatives implemented by various government and non-government entities to enhance renal health are key factors contributing to creatinine measurement market growth over 2022-2028. Nearly 1 in 7 adults in the U.S. suffer from some form of chronic kidney disease. In order to address these issues, various organizations are introducing new initiatives aimed at promoting renal health. For instance, in March 2021, NephCure Kidney International together with HEAL Collaborative (Health Education Advocacy and Learning, Inc.) launched the Health Equity Initiative, designed to address access care and research for diverse families living with protein-spilling, chronic kidney ailments. Developments such as these could boost demand for creatinine measurement solutions over the years ahead.
With regards to sample type, the creatinine measurement market from the urine segment is anticipatedto amass significant proceeds by 2028. Urine creatinine clearance tests are used to measure the amount of creatinine present in a urine sample collected over 24 hours. Although considered less convenient than blood/serum creatinine measurement, this method is essential for the diagnosis of certain kidney conditions, especially in patients with marked decrease in muscle mass or large muscle mass.
From a regional standpoint, Asia Pacific creatinine measurement market is predicted to depict a strong growth rate through 2028, owing to factors such as rising CKD prevalence in the region. Singapore, for instance, ranks 7th in the world for new cases of kidney failure. In response to these conditions, several players in the regional industry are developing novel methods for creatinine measurement to optimize renal health. For example, in December 2020, Nitto Denko Asia Technical Centre (NAT) began the testing of ACT by Zensorium, its early-detection device for kidney ailments at SGH (Singapore General Hospital). The solution is designed to conduct urine testing to identify increased levels of albumin and creatinine, which can contribute to higher risk of CKD onset and progression especially in hypertension and diabetes patients.
Major players operating in the creatinine measurement industry include F. Hoffmann-la Roche, Randox Laboratories, Abbott, Pointe Scientific, Danaher, Sentinel Diagnostics, Siemens Healthineers, DIALAB, Diazyme Laboratories, and Thermo Fisher Scientific. Partnerships, product launches and acquisitions, among others are the main strategies being employed by these firms to expand their presence in the global market.
Most of the symptoms associated the novel coronavirus pandemic have manifested in the form of respiratory conditions, ranging in severity from mild to life-threatening. However, COVID-19 patients are increasingly displaying signs of kidney damage because of mild proteinuria, hematuria, acute kidney injury or elevations in creatinine levels due to kidney tropism of the virus, which could amplify demand for creatinine measurement solutions. More than 40% of patients admitted owing to COVID-19 display some form of abnormal kidney function. Also, people with existing kidney ailments and other chronic ailments are at higher risk of infection, due to compromised immune systems, making renal health a major priority. In response to these issues, various guidelines like the IFFC Guide on COVID-19 recommend creatinine measurement in patients with COVID-19 for timely detection of potential kidney injury.
Market, by Product
Market, by Sample Type
Market, by Test Type
Market, by End-use
The above information is provided for the following regions and countries: